Item 7.01 Regulation FD Disclosure On May 21, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as “L-Annamycin” or “naxtarubicin”), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. A copy of the press release and abstract are attached to this report as Exhibit 99.1 and 99.2, respectively, and are incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
MBRX Moleculin Biotech, Inc. - 8-K
Accession
0001437749-26-0182427.019.01
Item 7.01 - Regulation FD Disclosure
164 words
Item 9.01 - Financial Statements and Exhibits
31 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 21, 2026 99.2 Abstract 104 Cover page Interactive Data File (formatted as Inline XBRL document)